Sacubitril/valsartan is recognised nationally by the CaReMe UK Partnership as a first-line treatment option for chronic HFrEF, to be given in combination with a beta-blocker and MRA.1
ENTRESTO and the CaReMe UK Partnership
Watch Professor Iain Squire and Dr Jim Moore, board members of CaReMe UK, discuss the need for a ‘modern’ HF management algorithm, as well as the rationale for positioning sacubitril/valsartan as a first-line treatment option.1
Speaker Disclosures – Dr Jim Moore has received honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk and Roche for various activities including attending and participating in educational events and advisory boards, (National Cardiac Pathways Improvement Programme – Clinical Leadership Group, Observer on the British Society for Heart Failure Board, Member of the National Heart Failure Audit Domain Expert Group, NICE Guideline Committee member – Chronic Heart Failure 2018).
Professor Iain Squire has received honoraria for participating in educational activities and/or advisory boards for Novartis, Vifor Pharma and Boehringer Ingelheim. His employer has received funding for research from Novartis, Vifor Pharma, Boehringer Ingelheim, Merck and AstraZeneca.
ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.2
* CaReMe UK Partnership is a collaboration between the British Cardiovascular Society, the Renal Association, the Association of British Clinical Diabetologists, the Primary Care Cardiovascular Society and the Primary Care Diabetes Society.
† ENTRESTO contains valsartan, and therefore should not be coadministered with another ARB-containing product. Stop using an ACE inhibitor for 36 hours before starting ENTRESTO.2
ACE, angiotensin-converting enzyme; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist.
- CaReMe UK Partnership. Modified from Management algorithm for NICE guideline “Chronic Heart Failure in Adults: diagnosis & management”. Available at: https://www.nice.org.uk/guidance/ng106. (Accessed September 2021).
- ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/7751/smpc. (Accessed September 2021).
- Enalapril Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/6105/smpc. (Accessed September 2021).